Backed by GE Ventures, Mayo Clinic Ventures, and DFJ, the Vineti team brings together a hybrid of experts in user-centric, regulated industry software and analytics development, as well as commercial therapeutics development and manufacturing.
Uniting all of us is a belief that we are transitioning from one-size-fits-all medicine to individualized therapies as the standard of care. To achieve the full potential of this vision, Vineti is working to build technologies that support therapeutic development and delivery and keep pace with the leading therapeutic science. Together with our leading pharmaceutical partners, we are doing just that with our independent Vineti solution.
What is the thinking behind our name? Vineti is an ancient term of wisdom that invokes the idea of progress by removing obstacles and guiding towards a goal.
Before co-founding Vineti, Amy focused on healthcare new business creation for GE Ventures/ healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was co-founder and Executive Director of Proposition 71, California’s $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Amy holds an MBA and MA/BA in English from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute.
Heidi has been an Operations Executive in the Biotechnology industry for over 25 years and is a Co-founder of Vineti. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Previously, Heidi was the Global COO for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations and ten years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.
Razmik is a leading Business Software Executive. He is currently CTO and Co-founder for Vineti. He is formerly CTO for EMC Documentum product family, a leading Enterprise Content Management platform and solutions for Fortune 500 companies. Razmik was one of the original designers of the Documentum platform. He was a founding member of the Documentum team and helped grow it to become a leading force in the Enterprise Content Management industry, with an IPO in 1996 and eventual acquisition by EMC in 2003 for $1.7 Billion. Razmik is the author of several patents and co-author of several technical books. He is also an investor and advisor to multiple high tech companies.
Dr. Malek Faham is Chief Scientific Officer and Co-founder of Vineti. He was formerly co-founder and CSO of Sequenta Inc, where he led technology development, scientific direction, clinical validation, and operation from the initial vision in 2008 of the potential of immune receptor repertoire sequencing to the company’s acquisition in 2015 by Adaptive Biotechnologies. Previously, Dr. Faham co-founded Parallele Bioscience, Inc. in 2001 and served as its Director for Research until its acquisition by Affymetrix in 2005. He then served as VP of Oncology Technology Research at Affymetrix until 2008. He has published more than 50 peer-reviewed articles and has over 100 issued and pending patents. Dr. Faham received his MD, Ph.D. in biochemistry and human genetics and Psychiatry residency training from University of California San Francisco, and had his post doctoral training with Professor Ronald W. Davis in the Stanford Genome Technology Center.
Chris brings more than 20 years of financial leadership experience from smaller startups to larger public companies. At Vineti, Chris is responsible for all administrative and support functions including Finance, Accounting, Human Resources and Legal operations. Before joining Vineti, Chris served as the VP of Finance & Operations at Grand Rounds, a digital health company. Prior to that, Chris served as CFO at Flite as well as in various senior leadership roles at Avid Technologies, Infineon, and Siemens AG. Chris received his BA from the University of Michigan, Ann Arbor and received a MBA from the Middlebury Institute at Monterey.
April has been a leader in biotechnology and healthcare for more than a decade. She has a proven track record in product and market strategies, communications, and making biotechnology innovations accessible, scalable, and engaging. Before joining Vineti, April led an innovations team at Invitae, a genetic information company, and also served as Invitae’s head of Product. She previously worked in product strategy and product marketing for Life Technologies, focusing on genomic diagnostic analysis in cancer, and for Navigenics, a pioneering personal genomics start-up. Before starting her work in biotech, April was an award-winning journalist, author, and editor, with hundreds of articles and a series of university textbooks published under her byline. She has a BA from Pomona College and an MA in journalism and communications from the University of California at Berkeley.
Risa leads the GE Ventures, New Business Creation team. The team has started companies in healthcare and other industries including: Evidation Health, Current powered by GE, and Menlo Microsystems. Risa joined the GE Ventures team from Kleiner Perkins Caufield & Byers where she was a partner for 10 years. While at Kleiner Perkins Caufield & Byers, Risa incubated several companies and was the founding CEO of two. Risa has invested in and held board director or observer roles in over a dozen healthcare companies including: Corthera (acquired by Novartis), Epizyme (NASDAQ: EPZM), Foundation Medicine (NASDAQ:FMI), Ilex Oncology (acquired by Genzyme), Orexigen (NASDAQ:OREX), Pacific Biosciences (NASDAQ:PACB), Triangle Pharmaceuticals (acquired by Gilead), Trius (acquired by Cubist), and Veracyte (NASDAQ:VCYT). Risa holds a degree in genetics and development with distinction from the University of Illinois, a Ph.D. in immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.
Emily is a partner at DFJ and has spent more than a decade working with early stage companies. Emily’s primary areas of interest include consumer and mobile technology, healthcare technologies and marketplaces. Her investments include BetterUp, Elation Health, Livongo, Redfin, Shift, and Wellframe. Emily started her career at DFJ and spent eight years at the firm where she sourced and became actively involved in consumer and enterprise investments including Meebo (acquired by Google), Flux (acquired by MTVNetworks), Kudo (acquired by Google), Redfin, ShareThis, and RichRelevance. Recently, she was an advisor to Pulse Networks (acquired by LinkedIn), HealthTap, and PoshMark. She holds a BA with honors and distinction in political philosophy and an MBA, both from Stanford University.
Nigel has worked in a variety of executive positions in GE Healthcare Life Sciences, most recently as VP of the BioProcess business from 2008-2016 and currently works as an Advisor to the CEO. Previously Nigel had been VP for Chemistry Technology at AstraZeneca. Prior to entering industry he had spent 16 years in academic research in medicine and molecular biology for the UK Medical Research Council and in Germany at EMBL, Heidelberg. Nigel received his first degree in Natural Sciences from the University of Cambridge, U.K in 1981 and his Ph.D. in Biochemistry from the University of Kent, U.K. in 1985.
Rowan is Head of J&J Innovation, CA. She leads the team responsible for identifying, investing and partnering with the entrepreneurial ecosystem across the J&J Pharmaceutical, Medical Device and Consumer sectors. Prior to J&J Rowan served as Head of Healthcare Investing at GE Ventures where she was a member of the Vitruvian founding team. There she led the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership with a particular focus on digital health, data analytics and precision medicine. Previously she spent 11 years as a Partner at Mohr Davidow Ventures, was a very early employee at Rosetta Inpharmatics, and Incyte Genomics. Rowan holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a post-doctoral fellow at the University of California, San Francisco.